Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide

详细信息    查看全文

• 作者：Shintaro Haruki ; Yuichiro Minami ; Atsushi Suzuki ; Nobuhisa Hagiwara
• 关键词：Antiarrhythmic agents ; Hypertrophic cardiomyopathy ; Obstruction
• 刊名：Heart and Vessels
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：30
• 期：5
• 页码：604-610
• 全文大小：487 KB
• 参考文献：1.Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. J Am Med Assoc 287:1308-320
  2.Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775-85CrossRef PubMed
  3.McKenna WJ, Behr ER (2002) Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 87:169-76CrossRef PubMed PubMed Central
  4.Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011) Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17:459-64CrossRef PubMed
  5.Fujita E, Nakanishi T, Nishizawa T, Hagiwara N, Matsuoka R (2013) Mutations in the cardiac troponin T gene show various prognoses in Japanese patients with hypertrophic cardiomyopathy. Heart Vessel 28:785-94CrossRef
  6.Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessel 28:742-49CrossRef
  7.Okayama S, Soeda T, Kawakami R, Takami Y, Somekawa S, Ueda T, Sugawara Y, Matsumoto T, Sung JH, Nishida T, Uemura S, Saito Y (2013) Evaluation of coronary artery disease and cardiac morphology and function in patients with hypertrophic cardiomyopathy, using cardiac computed tomography. Heart Vessels. doi:10.-007/?s00380-013-0452-9 PubMed
  8.Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation, American Heart Association Task Force on Practice G (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212–e260CrossRef PubMed
  9.Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-03CrossRef PubMed
  10.Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr (1964) Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29:84-8CrossRef PubMed
  11.Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE (1981) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 48:545-53CrossRef PubMed
  12.Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ (2005) Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 45:1251-258CrossRef PubMed
  13.The Sicilian gambit (1991) A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task force of the working group on arrhythmias of the European Society of Cardiology. Circulation 84:1831-851CrossRef
  14.Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-713CrossRef PubMed
  15.Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92:1680-692CrossRef PubMed
  16.Sherrid MV, Pearle G, Gunsburg DZ (1998) Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97:41-7CrossRef PubMed
  17.Thompson DS, Naqvi N, Juul SM, Swanton RH, Coltart DJ, Jenkins BS, Webb-Peploe MM (1980) Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 44:488-98CrossRef PubMed PubMed Central
  18.Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV (1985) Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72:853-64CrossRef PubMed
  19.Anderson DM, Raff GL, Ports TA, Brundage
• 作者单位：Shintaro Haruki (1)
  Yuichiro Minami (1)
  Atsushi Suzuki (1)
  Nobuhisa Hagiwara (1)
  
  1. Department of Cardiology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Cardiac Surgery
  Vascular Surgery
  Biomedical Engineering
  Interventional Radiology
  Ultrasound
  
• 出版者：Springer Japan
• ISSN：1615-2573

文摘

It remains unclear whether flecainide, a Class I antiarrhythmic drug, improves left ventricular pressure gradient (LVPG) or symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Our study evaluated the long-term efficacy of flecainide, compared to disopyramide, when administered orally, on LVPG and symptoms in obstructive HCM patients. Among 164 obstructive HCM patients, 15 were administered oral flecainide therapy and 33 administered oral disopyramide therapy. LVPG declined from 79.8 ± 36.6 to 39.2 ± 36.7 mmHg (p = 0.003) after flecainide therapy and from 74.5 ± 26.4 to 31.4 ± 24.8 mmHg (p < 0.001) after disopyramide therapy. The percent reduction in LVPG was ?7.9 ± 43.2 % in patients treated with flecainide, comparable to the results for those treated with disopyramide (?7.1 ± 33.0 %; p = 0.425). We found no significant differences in improvement in NYHA functional class between patients treated with flecainide and those treated with disopyramide (p = 0.331). Patients treated with flecainide exhibited no significant adverse side effects, and there was no need for myectomy or alcohol septal ablation to reduce LVPG and symptoms. Improvements in LVPG and symptoms were similar in patients treated with flecainide and patients treated with disopyramide, suggesting that flecainide is a potentially useful alternative for symptomatic obstructive HCM patients, particularly those with disopyramide-induced vagolytic side effects, narrow angle glaucoma, or prostatic hyperplasia and pre-existing urination difficulties. Our data must be viewed with caution, however, in view of the small number of study patients. Flecainide therapy will require further proof of safety before it can be routinely recommended in patients with symptomatic obstructive HCM. Keywords Antiarrhythmic agents Hypertrophic cardiomyopathy Obstruction